Depakote
Product Images NDC 0074-6215

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Depakote (NDC 0074-6215). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Abbvie Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

The Following Structure Divalproex Sodium Is A Stable Co-ordination Compound Comprised Of Sodium Valproate And Valproic Acid In A 1:1 Molar Relationship And Formed During The Partial Neutralization Of Valproic Acid With 0.5 Equivalent Of Sodium Hydroxide. Chemically It Is Designated As Sodium Hydrogen Bis(2-propylpentanoate). (Depakote Tablets Spl 01)

Chemical structure diagram showing the molecular structure of the active ingredient in Depakote, depicting atoms and bonds including sodium (Na) components and hydrocarbon chains in the polymer structure.*

FDA Label Image

Figure 1 (Depakote Tablets Spl 02)

A bar graph depicting percentages comparing PBO (placebo) and DVPX (Depakote) outcomes across two studies, labeled Study 1 (YMRS) and Study 2 (MRS). The percentages for DVPX are 60% in Study 1 and 58% in Study 2, while PBO values are 26% and 29%, respectively.*

FDA Label Image

Figure 2 (Depakote Tablets Spl 03)

A line graph comparing the percentage reduction in CPS rate for patients treated with Depakote versus placebo. The y-axis shows percentage reduction in CPS rate ranging from -100% (worsening) to 100% (improvement), while the x-axis shows the percentage of patients from 100% to 0%. Two lines represent Depakote (solid) and placebo (dashed), illustrating greater improvement with Depakote.*

FDA Label Image

Figure 3 (Depakote Tablets Spl 04)

A figure illustrating the percentage reduction in CPS rate plotted against the percentage of patients, comparing high dose (solid line) and low dose (dashed line) groups. The vertical axis shows improvement or worsening, with a baseline of no change at 0%, and the horizontal axis represents the percentage of patients from 0 to 100.*

FDA Label Image

Figure 4 (Depakote Tablets Spl 05)

A bar chart comparing the results of two studies labeled Study 1 and Study 2. Each study shows a comparison between Placebo and Depakote with numerical scales on the vertical axis ranging from 0 to 6. Depakote bars are lower than Placebo in both studies, indicating a measured difference.*

FDA Label Image

Ndc 0074-6212-13 100 Tablets Depakote®divalproex Sodium Delayed-release Tablets 125 mg Valproic Acid Activity Dispense The Accompanying Medication Guide To Each Patient. Rx Only Abbvie (Depakote Tablets Spl 06)

Depakote 125 mg Divalproex Sodium delayed-release tablets label by AbbVie Inc. Packaging indicates 100 tablets per bottle. The label highlights 125 mg strength with valproic acid activity and includes storage, dispensing, and manufacturer information. Bottle seal warnings and product identification details are also present.*

FDA Label Image

Ndc 0074-6214-53 500 Tablets Depakote®divalproex Sodium Delayed-release Tablets 250 mg Valproic Acid Activity Dispense The Accompanying Medication Guide To Each Patient Rx Only Abbvie (Depakote Tablets Spl 07)

Depakote 125 mg delayed-release tablets label showing active ingredient divalproex sodium equivalent to valproic acid, manufactured by AbbVie Inc. The label includes the NDC 0074-7325-13 and states the packaging contains 100 tablets. It has storage instructions below 86°F (30°C) and warnings about seal integrity. The label indicates Rx only status and highlights the salmon-pink colored tablet identification.*

FDA Label Image

Ndc 0074-6214-13 100 Tablets Depakote®divalproex Sodium Delayed-release Tablets 250 mg Valproic Acid Activity Do Not Accept If Seal Over Bottle Opening Is Broken Or Missing. Dispense The Accompanying Medication Guide To Each Patient.rx Only Abbvie (Depakote Tablets Spl 08)

Depakote 250 mg delayed-release tablets label showing active ingredient divalproex sodium with valproic acid activity. The label indicates 100 tablets per bottle, includes NDC 0074-6214-13, and is manufactured by AbbVie Inc. in North Chicago, IL. The label advises dispensing the accompanying medication guide and includes a barcode and lot information area.*

FDA Label Image

Ndc 0074-6215-13 100 Tablets Depakote®divalproex Sodium Delayed-release Tablets 500 mg Valproic Acid Activity Dispense The Accompanying Medication Guide To Each Patient. Rx Only Abbvie (Depakote Tablets Spl 09)

Depakote 500 mg Divalproex Sodium Delayed-Release Tablets label showing a package of 100 tablets. The label includes the NDC 0074-6215-13, manufacturer AbbVie Inc., and storage instructions to keep below 86°F in a light-resistant container. The label notes each tablet contains 500 mg valproic acid activity and is for prescription use only.*

FDA Label Image

Depakote Tablets Spl 0a

Depakote 500 mg delayed-release tablets label by AbbVie Inc. The label includes the NDC 0074-7327-13 and states 100 tablets per bottle. It specifies the active ingredient as divalproex sodium with valproic acid activity, prescription-only status, and storage instructions. The label features a barcode and manufacturer details.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.